Arpit Rao, MD, Baylor College of Medicine, Houston, TX, discusses the addition of an agent to the standard of care (SOC), androgen deprivation therapy (ADT), for subsets of prostate cancer (PC) patients. Dr Rao explains how there are clear subsets of patients where treatment should be intensified, for instance, the PROpel (NCT03732820) and MAGNITUDE (NCT03748641) trials demonstrated how patients who harbor homologous repair (HR) mutations generally perform poorly with treatment and so treatment should be intensified. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.
